DiaMedica Therapeutics DMAC 深 滬
等待開盤 04-02 09:30:00 美东时间
6.42
-0.350
-5.17%
華盛通- 最 高7.0157
- 今 開6.80
- 成交量 23.25万股
- 最 低 6.40
- 昨 收 6.77
- 總市值 3.46亿
- 52周最高 10.4195
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 3.2805
- 委 比 -92.50%
- 總股本 5388.25万
- 歷史最高 10.88
- 量 比 0.91
- 振 幅 9.09%
- 歷史最低 1.12
- 每 手 1
- 風險率 1.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
DiaMedica Therapeutics to Report Full-Year 2025 Financial Results and Host Conference Call
DiaMedica Therapeutics to Report Full-Year 2025 Financial Results and Host Conference Call DiaMedica will release its full-year 2025 financial results after the markets close on March 30, 2026. A conference call to discuss the results is scheduled for March 31, 2026, at 7:00 AM CDT, with webcast acc
03-23 20:25
DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced
03-05 20:38
Health Canada Clears DiaMedica Phase 2 DM199 Preeclampsia Trial
Health Canada Clears DiaMedica Phase 2 DM199 Preeclampsia Trial DiaMedica Therapeutics Inc. said it received a No Objection Letter from Health Canada clearing its Clinical Trial Application to evaluate DM199 in a Phase 2 trial for early-onset preeclampsia. The company said the clearance allows it to
03-05 20:35
DiaMedica Therapeutics to Participate in TD Cowen, Barclays, and Leerink Healthcare Conferences
DiaMedica Therapeutics to Participate in TD Cowen, Barclays, and Leerink Healthcare Conferences DiaMedica Therapeutics Inc. said management will participate in three investor conferences in March 2026: a TD Cowen 46th Annual Healthcare Conference fireside chat in Boston on March 2, 2026; a Barclays
02-24 22:23
DiaMedica Therapeutics Raises Capital via Share Offering
Diamedica Therapeutics ( ($DMAC) ) has issued an announcement. On December 19, ...
01-05 22:49
BRIEF-Diamedica Therapeutics Provides Dm199 Preeclampsia Program Update
Dec 18 (Reuters) - DiaMedica Therapeutics Inc DMAC.O: DIAMEDICA THERAPEUTICS PROVIDES DM199 PREECLAMPSIA PROGRAM UPDATE FOLLOWING PRE-IND MEETING WITH FDA DIAMEDICA THERAPEUTICS INC - FDA REQUESTS ADD...
2025-12-18 22:12
DiaMedica Therapeutics Completes Productive In-Person Pre-IND Meeting With FDA For Planned Study Evaluating DM199 In Preeclampsia
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced
2025-12-18 21:46
10% Owner Jan Stahlberg Reports Acquisition of Common Shares of DiaMedica Therapeutics Inc
Jan Stahlberg, a 10% owner, reported the acquisition of common shares of DiaMedica Therapeutics Inc. The Form 4 was filed by multiple reporting persons, including Jan Stahlberg and other reporting ben...
2025-12-09 06:15
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
